Beraprost Sodium Modified Release

DRUG4 trials

Sponsors

Lung Biotechnology PBC

Conditions

Pulmonary Arterial Hypertension

Phase 2

A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients

CompletedNCT00781885

Lung Biotechnology PBCPulmonary Arterial Hypertension

Start: 2009-01-31End: 2010-09-30Updated: 2020-06-09

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

CompletedNCT00792571

Lung Biotechnology PBCPulmonary Arterial Hypertension

Start: 2009-02-28End: 2013-11-30Updated: 2019-12-26

Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)

CompletedNCT00989963

Lung Biotechnology PBCPulmonary Arterial Hypertension

Start: 2010-02-01End: 2011-09-13Updated: 2020-09-30

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

CompletedNCT00990314

Lung Biotechnology PBCPulmonary Arterial Hypertension

Start: 2009-11-30End: 2013-11-30Updated: 2019-09-16